COMPARATIVE PHARMACOECONOMIC ANALYSIS OF THE APPLICATION OF POSACONAZOLE, FLUCONAZOLE AND ITRACONAZOLE WITH THE PURPOSE OF PRIMARY PREVENTION OF INVASIVE FUNGAL INFECTION IN PATIENTS WITH NEUTROPENIA DURING CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Krysanov, I [1 ]
Krysanova, V [2 ]
机构：
[1] Moscow Natl Univ Food Prod, Postgrad Med Inst, Moscow, Russia
[2] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1691
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY61
引用
收藏
页码：A532 / A532
页数：1
相关论文
共 37 条
  • [1] Prophylaxis of invasive fungal infection with posaconazole or standard azoles (fluconazole/itraconazole) in patients with acute myelogenous leukaemia or myelodysplastic syndrome and chemotherapy-induced neutropenia: results of a randomised multicentre trial
    Maertens, J
    Cornely, OA
    Winston, DJ
    Perfect, J
    Helfgott, D
    Ullmann, AJ
    Holowiecki, J
    Stockelberg, D
    Goh, YT
    Petrini, M
    Walsh, T
    Boparai, N
    Hardalo, C
    Angulo-Gonzalez, D
    BONE MARROW TRANSPLANTATION, 2006, 37 : S163 - S163
  • [2] Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction - Chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome
    Mattiuzzi, GN
    Estey, E
    Raad, I
    Giles, F
    Cortes, J
    Shen, Y
    Kontoyiannis, D
    Koller, C
    Munsell, M
    Beran, M
    Kantarjian, H
    CANCER, 2003, 97 (02) : 450 - 456
  • [3] Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital
    Chan, Thomas S. Y.
    Marcella, Stephen W.
    Gill, Harinder
    Hwang, Yu-Yan
    Kwong, Yok-Lam
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (01) : 77 - 83
  • [4] Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
    Rafael Cámara
    Irmina Gozalbo
    Manuel Jurado
    Jaime Sanz
    Belén Aragón
    Santiago Grau
    Advances in Therapy, 2017, 34 : 2104 - 2119
  • [5] Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
    Camara, Rafael
    Gozalbo, Irmina
    Jurado, Manuel
    Sanz, Jaime
    Aragon, Belen
    Grau, Santiago
    ADVANCES IN THERAPY, 2017, 34 (09) : 2104 - 2119
  • [6] Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Tan, Gloria
    Teng, Monica
    Tee, Caroline
    Tan, Ban Hock
    Ong, Benjamin
    Lim, Boon Peng
    Chai, Louis Yi Ann
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) : 376 - 386
  • [7] Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    Krishna, Gopal
    AbuTarif, Malaz
    Xuan, Fengjuan
    Martinho, Monika
    Angulo, David
    Cornely, Oliver A.
    PHARMACOTHERAPY, 2008, 28 (10): : 1223 - 1232
  • [8] Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    AbuTarif, M. A.
    Krishna, G.
    Statkevich, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (02) : 397 - 405
  • [9] Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis
    Dranitsaris, George
    Khoury, Haytham
    SUPPORTIVE CARE IN CANCER, 2011, 19 (11) : 1807 - 1813
  • [10] Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis
    George Dranitsaris
    Haytham Khoury
    Supportive Care in Cancer, 2011, 19 : 1807 - 1813
1234